# Repertoire Immune Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/repertoire-immune-medicines

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.repertoire.com
- Total disclosed funding: $189M
- Latest round: Series B (Apr 13, 2021)
- Investors on record: 6

## About

Repertoire Immune Medicines, Inc., based in the US, focuses on developing innovative immune therapies to combat cancer and autoimmune diseases, utilizing cutting-edge technology to enhance patient outcomes.Repertoire Immune Medicines, Inc. specializes in the development of immune therapies targeting cancer and autoimmune diseases. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company has received funding through four deals, with its most recent Series B funding round on April 13, 2021, raising USD 189.00 mn from investors including Carlyle Group and Flagship Pioneering. The company’s founders are Ewen Cameron and Justin Khanna, while Torben Nissen serves as the CEO. Repertoire has achieved a current company valuation of USD 474.32 mn.Repertoire Immune Medicines specializes in the development of innovative immune therapies targeting cancer and autoimmune diseases. Central to their offerings is the proprietary DECODE platform, which provides in-depth insights into immune synapses—key components of the adaptive immune system. This technology allows for the identification of unique T cell codes and their interactions, enabling the design of programmable immune medicines tailored to treat a variety of solid and hematological cancers, as well as autoimmune conditions. The company aims to deliver these transformative therapies to healthcare institutions and patients in North America and Europe, with ongoing efforts to penetrate additional global markets. By focusing on the precision of immune medicine, Repertoire seeks to redefine treatment paradigms and improve patient outcomes across diverse therapeutic areas.Repertoire Immune Medicines generates revenue through partnerships and collaborations with biopharmaceutical firms and research institutions, focusing on the advancement of their therapeutic candidates. Transactions typically involve contractual agreements for the development and commercialization of their proprietary therapies, which may include milestone payments and royalties tied to product sales. The company’s pipeline includes both flagship and emerging products designed for targeted cancer treatment and the management of autoimmune diseases. While specific pricing structures and transaction details are not publicly disclosed, the firm is positioned to engage in B2B arrangements, facilitating access to its advanced immune medicines through strategic alliances and research collaborations.In April 2021, Repertoire Immune Medicines, Inc. raised USD 189.00 mn in Series B funding to support various growth initiatives. The company plans to expand its proprietary DECODE discovery platform and accelerate its clinical and preclinical pipeline, along with hiring new teams and enhancing manufacturing capabilities. The funding will also facilitate exploration into new markets in North America and Europe, with potential expansions into Asia by 2023.

## Funding rounds

- Series B, Apr 13, 2021, $189M — Carlyle Group, Flagship Pioneering, Public Sector Pension Investment Board, Invus [DUP], SB Investment Advisers
- Series B, Mar 25, 2020 — JDRF T1D Fund

## Investors

- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series B
- Carlyle Group (https://capitalatlas.ai/funds/carlyle-group) — Series B
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series B
- Public Sector Pension Investment Board — Series B
- Invus [DUP] — Series B
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series B